Clinical trials have demonstrated varying degrees of weight loss depending on the specific agent: liraglutide typically achieves 5-8% weight loss over 56 weeks (SCALE trials), while semaglutide has shown approximately 15% weight loss over 68 weeks (STEP trials)
Recognising when GLP-1 medications may be suitable helps place these treatments in the correct context as part of a doctor-led weight management strategy rather than a standalone solution
Mao et al
Choosing folinic acid over Vitamin B12 depends on: The type of chemotherapy The patients nutritional status Genetic factors affecting nutrient use In some cases, folinic acid helps protect cells from methotrexates harm
Choosing the right peptide, or the correct combination, requires an understanding of how they function at a cellular level 1
If Youre Asking This Question, Youre Not Alone Over the past two years, one question has come up in nearly every employee benefits renewal meeting: Should our health plan cover GLP-1 medications? Medications such as Wegovy, Zepbound, Ozempic, and Mounjaro have transformed the treatment of obesity and diabetes